Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Primary Familial Brain Calcification with Leukoencephalopathy Associated with a Novel Variant in PDGFB
Movement Disorders
P15 - Poster Session 15 (5:30 PM-6:30 PM)
5-003

PFBC is a rare, inherited syndrome characterized by bilateral basal ganglia calcifications presenting with neuropsychiatric symptoms, seizures, headaches, and movement disorders. Mutations in PDGFB are known to cause autosomal dominant PFBC. Leukoencephalopathy has been rarely reported.

To describe a family with primary familial brain calcification (PFBC) and leukoencephalopathy associated with a novel variant in PDGFB.

We present three consecutive generations of a family with PFBC associated with a previously gnomAD-unreported variant in PDGFB. Publicly available computational (in silico) programs predicted protein dysfunction. We reviewed PubMed for cases of PFBC with leukoencephalopathy using search terms Fahr, primary familial brain calcifications, leukoencephalopathy, white matter changes, PDGFB, PDGFRB, SLC20A2, XPR1, JAM2, and MYORG.

A 24-year-old woman with episodic migraine, depression, and anxiety was found to have bilateral calcifications of the basal ganglia on head CT as well as frontally-predominant white matter hyperintensities on brain MRI.  Her father had mild cognitive impairment, bilateral action-induced hand tremor, and calcifications of the basal ganglia and cerebellum on head CT.  Her paternal grandmother had dementia, severe parkinsonism, calcifications of the basal ganglia and cerebellum on head CT, and confluent periventricular white matter hyperintensity on brain MRI. Genetic testing in the proband and her father revealed a novel PDGFB variant (NM_002608.3:c.298C>T p.(Arg100Cys)), unavailable in publicly available databases. Multiple in silico analysis tools predicted it to be pathogenic. Our literature review found three reports of PDGFB-associated PFBC with leukoencephalopathy.

Our report expands the list of PDGFB variants in PFBC and adds to the growing collection of genetic leukoencephalopathies. Clinicians should consider PDGFB disease in individuals with neurologic symptoms, familial leukoencephalopathy, and brain calcifications.

Authors/Disclosures
Jack Shen, Jr., MD (Wellstar)
PRESENTER
Dr. Shen has nothing to disclose.
No disclosure on file
Alberto J. Espay, MD, FAAN (University of Cincinnati) Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neuroderm. Dr. Espay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acadia. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acorda. Dr. Espay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kyowa Kirin. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sunovion. Dr. Espay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Herantis Pharma. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Supernus (formerly USWorldMeds). Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acadia. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Synaps Dx. Dr. Espay has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AskBio. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Supernus (formerly, USWorldMeds). Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amneal. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Avion Pharmaceuticals. The institution of Dr. Espay has received research support from NIH. The institution of Dr. Espay has received research support from Michael J Fox Foundation for Parkinson's Research. Dr. Espay has received intellectual property interests from a discovery or technology relating to health care. Dr. Espay has received publishing royalties from a publication relating to health care. Dr. Espay has received publishing royalties from a publication relating to health care. Dr. Espay has received publishing royalties from a publication relating to health care.
Emily J. Hill, MD (University of Cincinnati) Dr. Hill has nothing to disclose.